Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
Toronto, Ontario--(Newsfile Corp. - October 8, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce the Company has filed a preliminary prospectus supplement (the "Supplement") to its short form base shelf prospectus dated July 12, 2024 (the "Base Prospectus") in connection with a proposed public offering (the "Offering") of Class A common shares (the "Common Shares"). The Supplement was also filed with the U.S. Securities Exchange and Commission (the "SEC"), as part of a registration statement on Form-10, as amended, which was declared effective by the SEC on July 16, 2024, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.
安大略省多倫多市-(Newsfile corp-2024年10月8日)-心臟療法公司(納斯達克:CRDL)(tsx:CRDL)("Cardiol"或"公司"),一家臨床階段的生命科學公司,專注於心髒疾病的抗炎和抗纖維化治療的研究和臨床開發, 高興地宣佈公司已提交一份初步的增補招股說明書("補充協議"),對應於2024年7月12日的簡式基礎招股說明書("基礎說明書"), 與擬議的公開發行("發行")有關的A類普通股("普通股"). 進一步地,補充協議也已向美國證券交易委員會("SEC")提交,作爲一份Form-10修訂的註冊聲明的一部分,該聲明於2024年7月16日被SEC宣佈生效,在加拿大與美國建立的多管轄區披露制度的框架下。
The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis, and for general and administrative expenses, working capital and other expenses.
公司擬利用發行所得淨收益支持CardiolRx用於複發性心包炎治療,以及一般和行政費用、營運資金和其他支出。
Canaccord Genuity is acting as the sole bookrunner in connection with the Offering.
Canaccord Genuity將擔任發行的唯一包銷商。
The Offering is expected to be priced in the context of the market, with the final terms of the Offering to be determined at the time of pricing. There can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering. The closing of the Offering will be subject to customary closing conditions, including the listing of the Common Shares on the Toronto Stock Exchange (the "TSX") and the Nasdaq Capital Market (the "Nasdaq") and any required approvals of the TSX and Nasdaq.
預計發行將按照市場情況定價,發行的最終條款將在定價時確定。不能確保發行何時完成,以及發行的實際規模或條款。發行的結束將受到習慣的結束條件的約束,包括將普通股上市於多倫多證券交易所(tsx)和納斯達克資本市場(納斯達克),以及tsx和納斯達克的任何所需批准。
The Supplement and accompanying Base Prospectus contain important detailed information about the Offering. The Supplement and accompanying Base Prospectus can be found on SEDAR+ at and on EDGAR at www.sec.gov. Copies of the Supplement and accompanying Base Prospectus may also be obtained from Canaccord Genuity LLC, 1 Post Office Square, Suite 3000, Boston, Massachusetts 02109, Attn: Syndicate Department, or by email at prospectus@cgf.com. Prospective investors should read the Supplement and accompanying Base Prospectus and the other documents the Company has filed before making an investment decision.
增補協議和隨附的基礎招股說明書包含有關發行的重要詳細信息。 增補協議和隨附的基礎招股說明書可在SEDAR+和EDGAR的www.sec.gov上找到。 增補協議和隨附的基礎招股說明書副本也可從Canaccord Genuity LLC獲得,位於麻薩諸塞州波士頓市1號郵政廣場3000號套房,Suite 3000, 郵編02109,注意:承銷部門,或通過prospectus@cgf.com發郵件獲取。 準投資者應在作出投資決策之前閱讀增補協議和隨附的基礎招股說明書以及公司已提交的其他文件。
This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction.
此新聞稿不構成出售或要約出售任何省、州或司法管轄區的證券,該等出售或要約出售在該等省、州或司法管轄區內是不合法的,並且在任何此類證券根據任何該省、州或司法管轄區的證券法律法規進行註冊或合格之前,不得出售。
About Cardiol Therapeutics
關於Cardiol Therapeutics
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease.
Cardiol Therapeutics Inc.是一家臨床階段的生命科學公司,專注於研究和臨床開發抗炎和抗纖維化療法,用於治療心臟疾病。
Cautionary statement regarding forward-looking information:
關於前瞻性信息的警示聲明:
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Offering, the anticipated size and terms of the Offering, and the anticipated use of proceeds from the Offering. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission and Canadian securities regulators on April 1, 2024, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read the Supplement, the accompanying Base Prospectus and the documents incorporated by reference therein.
本新聞稿包含適用證券法律意義下的「前瞻信息」。除歷史事實陳述外,凡涉及Cardiol認爲、期望或預計未來可能發生的活動、事件或發展的陳述均屬「前瞻信息」。此處包含的前瞻信息可能涉及但不限於關於發行、發行預期規模和條款,以及發行所得款項預期用途的陳述。此處包含的前瞻信息反映了Cardiol基於目前可獲得信息的當前預期或信念,基於某些假設,並受各種已知和未知風險、不確定性和其他因素的影響,這些因素可能導致實際事件或結果與前瞻信息中表達或暗示的任何未來結果、表現或成就大不相同,並不是(也不應被視爲)未來表現的擔保。這些風險、不確定性和其他因素包括在公司於2024年4月1日向美國證券交易委員會和加拿大證券監管機構提交的20-F表格中提到的風險和不確定性,以及與產品商業化和臨床研究相關的風險和不確定性。這些假設、風險、不確定性和其他因素應該被仔細考慮,投資者不應過度依賴前瞻信息,並且此類信息可能不適用於其他用途。任何前瞻信息僅於本新聞稿日期起作用,除非適用證券法律有要求,否則Cardiol不承擔更新或修訂此類前瞻信息的任何意圖或義務,不論是否由新信息、未來事件或結果或其他因素引起。投資者被警告不要依賴這些前瞻陳述,並被鼓勵閱讀《附錄》、相應的基礎招股說明書以及其中引用的文件。
For further information, please contact:
如需更多信息,請聯繫:
Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com
投資者關係 Trevor Burns +1-289-910-0855 trevor.burns@cardiolrx.com
投資者關係 Trevor Burns +1-289-910-0855 trevor.burns@cardiolrx.com
譯文內容由第三人軟體翻譯。